Medifast, the company behind the Optavia weight loss program, reports Q2 earnings soon. Nobody is expecting a blowout. The stock has been under pressure for a while now, and the reasons are not exactly hidden.

The rise of GLP-1 drugs like Ozempic and Wegovy has rewritten the weight loss business. Why sign up for a meal replacement program when your doctor can prescribe something that actually works? I have watched that question hang over Medifast's revenue for several quarters now, and Q2 is unlikely to offer a different answer.

They have also been losing coaches. The company uses independent coaches to drive its Optavia program, and a shrinking coach base means fewer people out there selling the product. Hard to grow revenue when your sales force is contracting.

But it is not all bad news. Management has been cutting costs and finding productivity gains, which may have helped cushion the blow to margins even as revenue struggles. Companies facing a structural problem either get leaner or they die. The good ones protect cash flow and buy time to figure out the next chapter.

Yahoo Finance's preview lays out the case clearly, and it lines up with what I have seen in declining businesses before.

Now, I do not own Medifast and probably never will. Weight loss fads come and go, and when a whole industry gets disrupted by pharmaceutical breakthroughs, that is a tough tide to swim against. But there is a lesson here that applies to any stock you might be watching this earnings season.

When a company's core product gets undercut by a fundamental shift in the market, one earnings report is not going to tell you much. GLP-1 drugs are not going away. Medifast's management knows this, and they are presumably working on a pivot. Whether that pivot works is a multi-year question, not a quarterly one.

I have watched plenty of businesses over four decades of investing that faced exactly this kind of disruption. Some adapt and survive. Most slowly bleed. The ones that make it usually have strong balance sheets and patient management teams. Forget the headline revenue figure when the numbers come out. The balance sheet is what matters.

If you already own the stock, the earnings print matters for your cost basis and your patience. If you are thinking about buying it because it looks cheap, ask yourself whether you are catching a falling knife or buying a turnaround. Those are two very different things, and the earnings report alone probably will not tell you which one it is.

As always, this is perspective, not financial advice. Do your own homework, understand what you own, and do not let one quarterly report push you into or out of a position before you have thought it through.